Elevance Health (ELV) Announces Fiscal Q3 2025 Results

Financial Performance - Elevance Health, Inc. reported fiscal Q3 2025 operating revenue of $50.1 billion, reflecting a 12.0% increase year-over-year [1] - The diluted EPS for the quarter was $5.32, with adjusted diluted EPS reaching $6.03 [1] - Operating cash flow for fiscal Q3 2025 was $4.2 billion year-to-date, which is 0.8 times GAAP net income, a decrease of $0.9 billion year-over-year [3] Guidance and Shareholder Returns - The company reaffirmed its fiscal year 2025 benefit expense ratio guidance at around 90.0% and adjusted diluted EPS guidance of approximately $30.00 [2] - Elevance Health returned $3.3 billion of capital to shareholders year-to-date [2] Business Segments - Elevance Health operates through several segments: Health Benefits, CarelonRx, Carelon Services, and Corporate and Other [4] - The Health Benefits segment provides a variety of health plans and services, while CarelonRx manages pharmacy services [4] - Carelon Services integrates behavioral, physical, pharmacy, and social services to offer various healthcare-related services [4]